Nucleus Genomics Inc., a New York-based startup, is expanding its embryo testing technology in India through new partnerships with Indira IVF, which has 165 clinics in India.
Key Business and Financial Facts
Funding: The company has raised $32 million since its 2021 founding, with backing from investors such as Alexis Ohanian and Founders Fund.
Pricing: In the U.S., the service costs approximately $10,000 (excluding IVF costs). Pricing for the new international markets has not yet been established.
Scope: The founder describes this expansion as the largest deployment of “genetic optimization” technology to date.
Technology and Capabilities
Core Product: Nucleus uses PGT-P (Polygenic Risk Scoring) to screen embryos for the likelihood of developing diseases such as Alzheimer’s and diabetes.
Trait Prediction: The technology can also predict traits such as height and IQ.
Nucleus Preview
Methodology: The company claims lower DNA sequencing costs allow for a broader range of testing than traditional chromosomal screening.
Legal and Ethical Landscape
Regulatory Variance: While largely unregulated in the U.S., trait-based selection (e.g., for IQ or height or gender) is illegal in India. Consequently, Nucleus will only offer disease-risk data in that market.
Expert Criticism: The American Society for Reproductive Medicine has advised against the technology due to “predictive uncertainties” and ethical concerns.
Scientific Debate: Critics argue that genetic risk scores are currently inaccurate because they do not account for environmental factors, while Nucleus asserts its models are transparent and available for research review.
